Single center results of magnetic resonance imaging ultrasound guided fusion prostate biopsy obtained patients

Objective: We aimed to evaluate magnetic resonance imaging-ultrasound guided fusion prostate biopsy (MRI- US FPBx) results from a single center and compare with current literature. Material Methods: Between January 2016 July 2019, MRI-US FPBx pathological imaging of 358 men were retrospectively analyzed. PI-RADS scores determined as 3, 4 5 in 222 (62%), 107 (29.8%) 29 (8.1%) patients, respectively. Totally 454 lesions underwent FPBx. 303 (66.7%) scored 120 (26.4%) 31 (6.8%) 5. 315 (69.3%) peripheral zone, 26 (5.7%) central 111 (24.4%) transitional zone 2 them anterior fibromuscular stroma. Results: Overall cancer detection rate was 36.3%. Concerning rates, alone transrectal ultrasonography (TRUS-Bx) 27.6% 26.5%, Cancer only through PIRADS-3 4&5 6.9% 20.6%, Clinically significant (csPCa) rates evaluated csPCa overall (PCa) for TRUS-Bx, combined techniques 16.8%, 35.4% 39.2%, Results 11 patients benign. Conclusion: significantly increases success procedure. Regarding MRI technology, it is not appropriate consider stand-alone option without concomitant TRUS-Bx. Keywords: cancer; biopsy; MRI;